37.60
price down icon2.62%   -1.01
after-market Handel nachbörslich: 37.50 -0.10 -0.27%
loading
Schlusskurs vom Vortag:
$38.61
Offen:
$38.05
24-Stunden-Volumen:
3.09M
Relative Volume:
0.90
Marktkapitalisierung:
$3.70B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-13.98
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-0.79%
1M Leistung:
-38.21%
6M Leistung:
-71.80%
1J Leistung:
-69.79%
1-Tages-Spanne:
Value
$36.96
$38.15
1-Wochen-Bereich:
Value
$36.89
$39.55
52-Wochen-Spanne:
Value
$34.10
$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Firmenname
Sarepta Therapeutics Inc
Name
Telefon
617-274-4000
Name
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
1,372
Name
Twitter
@sarepta
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
SRPT's Discussions on Twitter

Vergleichen Sie SRPT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
37.60 3.72B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-08 Herabstufung Evercore ISI Outperform → In-line
2025-04-11 Eingeleitet Wells Fargo Overweight
2025-04-02 Hochstufung H.C. Wainwright Sell → Neutral
2025-03-31 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-02-11 Eingeleitet Deutsche Bank Hold
2024-11-27 Bestätigt Needham Buy
2024-11-25 Eingeleitet H.C. Wainwright Sell
2024-11-07 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-10-21 Eingeleitet Jefferies Buy
2024-10-10 Fortgesetzt Raymond James Outperform
2024-07-29 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-06-26 Herabstufung Citigroup Buy → Neutral
2024-05-31 Eingeleitet Piper Sandler Overweight
2024-05-28 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-05-14 Hochstufung Oppenheimer Perform → Outperform
2024-01-31 Eingeleitet BMO Capital Markets Outperform
2023-12-13 Fortgesetzt Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-11-21 Eingeleitet Wedbush Outperform
2023-10-31 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-10-31 Herabstufung Oppenheimer Outperform → Perform
2023-06-23 Herabstufung Evercore ISI Outperform → In-line
2023-04-26 Eingeleitet SMBC Nikko Outperform
2023-04-04 Eingeleitet Citigroup Buy
2023-03-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-12-22 Bestätigt BTIG Research Buy
2022-12-16 Hochstufung UBS Neutral → Buy
2022-04-04 Fortgesetzt Cantor Fitzgerald Overweight
2022-01-05 Bestätigt Needham Buy
2021-12-09 Hochstufung Oppenheimer Perform → Outperform
2021-11-05 Hochstufung JP Morgan Neutral → Overweight
2021-09-15 Hochstufung Guggenheim Neutral → Buy
2021-08-05 Hochstufung JP Morgan Underweight → Neutral
2021-06-15 Eingeleitet BTIG Research Buy
2021-04-26 Fortgesetzt Credit Suisse Neutral
2021-01-12 Herabstufung Citigroup Buy → Neutral
2021-01-11 Herabstufung UBS Buy → Neutral
2021-01-08 Herabstufung JP Morgan Overweight → Underweight
2021-01-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-01-08 Herabstufung Raymond James Outperform → Mkt Perform
2020-11-11 Eingeleitet Berenberg Hold
2020-10-28 Eingeleitet UBS Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-20 Herabstufung Credit Suisse Outperform → Neutral
2020-03-31 Eingeleitet Mizuho Buy
2019-11-01 Eingeleitet Guggenheim Buy
2019-08-21 Bestätigt Needham Buy
2019-07-09 Bestätigt Morgan Stanley Overweight
2019-07-01 Bestätigt RBC Capital Mkts Outperform
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-11 Bestätigt Credit Suisse Outperform
2018-10-12 Eingeleitet Bernstein Outperform
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-09-26 Bestätigt RBC Capital Mkts Outperform
2018-09-14 Fortgesetzt BofA/Merrill Buy
2018-09-06 Eingeleitet Credit Suisse Outperform
2018-08-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2018-06-21 Bestätigt Robert W. Baird Outperform
2018-06-20 Bestätigt Needham Buy
2018-06-19 Bestätigt H.C. Wainwright Buy
Alle ansehen

Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten

pulisher
May 29, 2025

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg.com

May 29, 2025
pulisher
May 29, 2025

July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq

May 29, 2025
pulisher
May 29, 2025

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

May 29, 2025
pulisher
May 27, 2025

Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About These 11 Stocks? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com

May 27, 2025
pulisher
May 26, 2025

Will Moderna's Rally Continue? - Forbes

May 26, 2025
pulisher
May 22, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent

May 22, 2025
pulisher
May 22, 2025

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive

May 22, 2025
pulisher
May 22, 2025

SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch

May 21, 2025
pulisher
May 21, 2025

Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance

May 19, 2025
pulisher
May 17, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids - BioSpace

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - itemonline.com

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire

May 16, 2025
pulisher
May 15, 2025

Nucleic Acid Therapeutics Market Trends, Size & Growth Forecast - openPR.com

May 15, 2025
pulisher
May 15, 2025

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Sarepta at BofA Conference: Navigating Challenges and Growth - Investing.com

May 14, 2025
pulisher
May 14, 2025

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns - TipRanks

May 14, 2025

Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):